ProQR Therapeutics N.V. reported a net loss of €10.1 million, or €0.10 per diluted share, for the first quarter ended March 31, 2025, compared to a net loss of €7.7 million, or €0.09 per diluted share, for the same period in 2024. The company's revenue for the quarter was €4.52 million, a slight increase from €4.45 million in Q1 2024.
Research and development costs increased to €12.3 million for the quarter, up from €9.3 million in the prior-year period, reflecting ongoing investments in the Axiomer platform. General and administrative costs decreased slightly to €3.2 million from €3.5 million in Q1 2024.
As of March 31, 2025, ProQR held €132.4 million in cash and cash equivalents. The company achieved a $1.0 million (€918,000) milestone in its collaboration agreement with Eli Lilly during the quarter. ProQR reiterated that the Clinical Trial Application for its lead program, AX-0810, remains on track for submission in Q2 2025, with initial clinical data expected in Q4 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.